The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.

ABSTRACT:

Background

Hepatitis C virus (HCV) has high global prevalence and can lead to liver complications and death. Access to direct-acting antivirals (DAAs) in Canada increased following several policy changes, however the real-world impact of expanded DAA access and increased use of these drugs is unknown.

Objective

We aimed to determine the early change in rates of HCV-related hospitalizations overall and HCV-related hospitalizations with hepatocellular carcinoma (HCC) after expanded DAA access.

Methods

We conducted a population-based time series analysis using national administrative health databases in Canada. Rates of HCV-related hospitalizations and HCV-related hospitalizations with HCC were enumerated monthly between April 2006 and March 2020. We used Autoregressive

SUBMITTER: Chu C 

PROVIDER: S-EPMC10409286 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature